Regulatory approval

Published by the Health Canada.

Health Canada approved binimetinib, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

This is written in the approval document as:

MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.

Citation

Pfizer Canada ULC. Mektovi (binimetinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00060288.PDF. Published March 2021. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HC (1) BRAF p.V600E Melanoma Binimetinib, Encorafenib
HC (1) BRAF p.V600K Melanoma Binimetinib, Encorafenib